Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present bluebird bio, Inc. (NASDAQ: BLUE).

Full DD Report for BLUE

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLUE)

CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
This article is part of a series on genomic medicine which is poised to transform healthcare over the next two decades. The first article entitled Genomic Medicine: Catch the Gene Therapy Wave is a primer providing context for company-specific articles in process. CRISPR Therapeutics (...
Source: SeekingAlpha
Date: May, 17 2018 16:05
bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent ?-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – - Oral presentation of interim data from patients treated with update...
Source: Business Wire
Date: May, 17 2018 09:00
bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
– Presentation will include safety and efficacy data from 21 patients treated in dose-escalation phase and early data from patients treated in dose-expansion phase – – Additional poster exploring the significance of MRD negativity in patients in this study to be pr...
Source: Business Wire
Date: May, 16 2018 17:00
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive Group, Sanmina, and Genesco - Discovering Underlying Factors of Influence
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerohive Networks, Inc. (NYSE:HIVE), M/I Homes, Inc. (NYSE:MHO), bluebird ...
Source: GlobeNewswire
Date: May, 15 2018 08:30
Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology
Recently, Bluebird Bio ( BLUE ) announced that it had expanded its collaboration with Medigene . This newly expanded license agreement increases the amount of T-cell Receptor (((TCR)) targets Bluebird is able to obtain in the coming years. T-cell Receptor therapies may offer a better al...
Source: SeekingAlpha
Date: May, 15 2018 03:36
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Medigene expands partnership with bluebird bio
German biotech Medigene AG expands its 2016 strategic alliance with bluebird bio (NASDAQ: BLUE ), increasing the number of T cell receptor projects to six from four. More news on: bluebird bio, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 14 2018 08:21

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-17156.60158.00159.00154.50351,895
2018-08-16154.95156.20156.75153.075997,910
2018-08-15155.55154.30156.40152.371341,375
2018-08-14157.35156.40158.90154.50397,596
2018-08-13158.20156.00159.10154.50514,956

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1734,25477,32444.2993Short
2018-08-1625,21686,69929.0845Cover
2018-08-1526,33076,27634.5194Cover
2018-08-1427,22689,52930.4103Cover
2018-08-1335,752163,99721.8004Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLUE.


About bluebird bio, Inc. (NASDAQ: BLUE)

Logo for bluebird bio, Inc. (NASDAQ: BLUE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BLUE)

      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 18 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 21 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 21 2018

       

       


      Daily Technical Chart for (NASDAQ: BLUE)

      Daily Technical Chart for (NASDAQ: BLUE)


      Stay tuned for daily updates and more on (NASDAQ: BLUE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BLUE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLUE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BLUE and does not buy, sell, or trade any shares of BLUE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/